East Coast, Boston
May 17, 2022
Welcome to hubXchange’s East Coast Immuno-Oncology Xchange 2022, bringing together executives from pharma and biotech to address and find solutions to the key issues faced in developing immuno-oncology therapies, through a series of roundtable discussions.
Discussion topics will cover Immune Biomarkers, Translational Research, Clinical Development, Combination Strategies and Next-Generation Therapies.
Take advantage of this unique highly interactive meeting format designed for maximum engagement and collaboration with your peers.
Please note this is an In-Person meeting with a hybrid option to join virtually.
VENUE DETAILS: Hilton Boston Woburn, 2 Forbes Road, Woburn MA 01801
Opening Address & Keynote: Immune Perspectives – Standing Back and Looking Forward
The immune system is possibly the most pleiotropic system constituting human biology. This coupled with the ever-increasing technological advancements in the field of immunology has generated a proverbial flood of knowledge relating to the immune systems involvement in almost of every aspect of human health and disease. Biopharmaceutical companies have harnessed the adaptability and power of the immune system to create multiple novel therapies that merely a decade ago would have been almost science fiction.
This presentation provides a perspective on the development of the field of immunology and also looks forward to opportunities that will generate further innovation.
Chief Medical Officer, Synexa
Justin Devine co-founded Synexa Life Sciences in 2003 and is the current serving Chief Medical Officer of Synexa Life Sciences. Justin is a physician and has further degree qualifications in both immunology and pharmacology.
His primary focus is to understand and meet both the challenges and objectives in the drug development industry by designing biomarker strategies to bring real insight to the challenges of clinical development.
He is particularly passionate about improving the drug development process by bringing innovative approaches to early phase research, including new ideas in translational medicine, bioinformatics and artificial intelligence.
Prognostic models: Integrated analysis of both spatial and multimarker information in the tumor microenvironment
- Utility and risk of cell segmentation in image analysis
- Hypothesis-generating vs hypothesis testing
- Precision, Recall, and AUCROC
- Regions of interest vs whole slide
- Training and validation datasets
Associate Director, Translational Medicine Oncology, AstraZeneca
Michael Surace, PhD, received a BS in Biology from James Madison University in 2004 before joining the Medical Automation Research Center in the Department of Pathology at the University of Virginia. He received his PhD from Virginia Tech in 2010. In 2015 he joined STCube Pharmaceuticals as a research scientist characterizing novel immune checkpoint inhibitor antibodies with multiplex immunofluorescesce and digital pathology image analysis to support mechanistic of action research. In 2017 he joined Medimmune/ AstraZeneca as a scientist developing and validating Multiplex IF panels. Since then he has continued developing mIF platform inside Translational Medicine Oncology, focusing on validation of panels, reproducibility across sites, and improving the image and data analysis pipelines for research and clinical trials to support the development of predictive and prognostic models incorporating multiple markers and spatial information.
Immuno-oncology biomarker discovery – Solutions for high-throughput & automation in screenings for gene and protein biomarkers?
- How do you best screen and study the interplay between tumor and immune
- Importance of high-throughput assays for biomarker discovery, especially in pre-
- Primary and secondary screening assays for Immune Biomarkers?
Global Product Manager, Thermo Fisher Scientific
Stefan Jellbauer is a Global Product Manager at Thermo Fisher Scientific
supporting the high-throughput QuantiGene gene expression platform and Luminex
instruments. After 10 years in academic research, Stefan joined
Affymetrix/eBioscience, where he worked in the roles of Field Application Scientist and Technical Specialist with Affymetrix and Thermo Fisher Scientific. He continued his work in cancer diagnostic research with Farcast Biosciences as Technical liaison
supporting BioPharma business development for an ex-vivo human tumor platform. Stefan re-joined the QuantiGene team at Thermo Fisher Scientific as a Product Manager.
Stefan received his Ph.D. in Biology (Medical Microbiology/Immunology) from Ludwig Maximilian’s University of Munich (Germany), focusing on tumor vaccination. He completed his post-doctoral work at the University of California, Irvine studying mucosal
immunology and host-pathogen interactions.
Spotlight Presentation – Next-Generation Spatial Proteomic Advancements for Quantitative Analysis of the Tissue Microenvironment
Multiplexed Ion Beam Imaging (MIBI™) technology enables high-definition spatial proteomics that uniquely provides actionable analysis of the tissue microenvironment—delivering novel insights into disease state, mechanism of action, and patient response. Learn how MIBI and MIBI-enabled Spatial Proteomic Services deliver:
- Identification and enumeration of cell populations
- Quantification of protein expression at the single-cell level
- Analysis of spatial interactions with unmatched depth
Business Director, Ionpath
Tad Hewit is the Business Director for Spatial Proteomics Services at Ionpath. He has over 20 years of experience in translational research, both in the laboratory and in business roles. Tad’s business career has focused on bringing innovative translational research services to biopharma, and he has been involved with several technologies from their early stages—such as patient-derived xenograft (PDX) tumor models and multiplex tumor imaging— that have later become industry-standard tools. Tad has a BS in Biology from Hampden-Sydney College, an MS in Biotechnology, and an MBA from Johns Hopkins University.
- The current probability of success of a drug reaching the market from initial research is staggeringly low, only ~3%, how can workflows in digital pathology improve on these statistics? Will a multi-omics approach in clinical trials help?
- What level of scientific validity do you believe is needed for a successful clinical trial? how good is the evidence today for the association between the biomarker and the clinical condition?
- Can you discuss the practicalities and obstacles in implementing digital pathology workflows into a clinical setting, this would include antibody validation?
- How can immunotherapy stakeholders work together so targeted treatment benefits can be seen by more patients-is the system broken?
Senior Director, Biomarker & Translational Strategy, Ultivue
Kirsty has 20 years of leadership experience addressing academic, clinical, biotechnology, clinical research organizations (CRO) and pharmaceutical industries through clinical/technical communication, sales support, and market intelligence. Most recently, Kirsty was instrumental in overseeing commercial applications for CodexDNA enabling rapid antibody development for vaccines and novel therapeutics using an automated cloning platform. Previously Kirsty held leadership roles in commercial development and scientific communications at Definiens (now part of AstraZeneca), Nanostring Technologies and ThermoFisher Scientific.
- Decipher the complexity of the tumor biology
- Get Insights from Tumor Microenvironment
- Strengthen the biologic hypothesis supporting your clinical programs
Vice President R&D, Veracyte
Jacques Fieschi-Meric received his PhD in Immunology from the Aix-Marseille University completed by a postdoctoral fellowship at the Commissariat à L’Energie Atomique. He served as R&D group leader at Beckman-Coulter, then Head of Project Management at QIAGEN. Today he is VP in charge of R&D at Veracyte